Natera Inc Discussion ASCO GI Results Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Ruizhi Qin - JPMorgan Chase & Co, Research Division - Analyst : I know you talked about having confidence that this is going to be enough to push for guideline changes. Just curious because I -- this data is based on a Japanese sample. So would this be sufficient? Or do you think guideline bodies would need to see U.S. data such as BESPOKE registry trial that I know you also have undergoing. And then just to confirm, in terms of the upcoming guideline update, do you expect that to be about both adjuvant escalation and de-escalation? Or do you think escalation is going to be more likely than de-escalation in the near term?

Question: Ruizhi Qin - JPMorgan Chase & Co, Research Division - Analyst : Okay. Got it. That's helpful. And then in terms of indication expansion, I know you mentioned generating new data for pancreatic and anal. Are these also the indications that you are prioritizing for as a next step for generating clinical utility evidence like you did for CRC? I know you mentioned that for these 2 indications, surveillance guidelines are already in place. So is that a reasonable way to think about it? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 24, 2022 / 9:30PM, NTRA.OQ - Natera Inc Discussion ASCO GI Results Call

Question: Kyle Alexander Mikson - Canaccord Genuity Corp., Research Division - Analyst : Congrats on the data. I just want to go to pharma quickly. So just obviously, guidelines and everything was really help on the kind of clinical side, but how could this type of data or maybe would the effect -- in the future could help maybe the companion diagnostic partnerships and the trials and so forth? Maybe how could those be accelerated? And just overall, I mean, how could the set of data really move the needle in terms of your kind of current and potential relationships with those biopharma companies? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 24, 2022 / 9:30PM, NTRA.OQ - Natera Inc Discussion ASCO GI Results Call

Question: Kyle Alexander Mikson - Canaccord Genuity Corp., Research Division - Analyst : Okay. Helpful. Just one quick follow-up. Could you guys share any time lines for the U.S. arm of the CIRCULATE study in terms of pacing of enrollment and how that's going to progress throughout the year, when we could see some initial data? I think I heard enrollment can start soon, but just wanted to get some sense for time lines.